Gilbert Halley E
SEC insider (Form 3/4/5 filer). CIK 0001601360. Director at CytomX Therapeutics, Inc. (CTMX) and 2 other issuers. 8 reported Form 4/5 transactions since Sep 2024; latest on Jun 17, 2026. Located in WESTLAKE VILLAGE, CA.
Companies Gilbert Halley E has filed insider reports for
- CytomX Therapeutics, Inc. (CTMX): Director
- Vaxcyte, Inc. (PCVX): Director
- Arcutis Biotherapeutics, Inc. (ARQT): Director
Gilbert Halley E
CIK: 0001601360
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Jun 17, 2026CTMX
CytomX Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
59K shares- - Jun 15, 2026PCVX
Vaxcyte, Inc.
AwardDirect2.3K shares- - Jun 5, 2026ARQT
Arcutis Biotherapeutics, Inc.
AwardDirect5.8K shares- - Nov 20, 2025ARQT
Arcutis Biotherapeutics, Inc.
ExerciseDirect12.2K shares at avg. $7.51$92K - Nov 20, 2025ARQT
Arcutis Biotherapeutics, Inc.
SaleDirect16.5K shares at avg. $27.55$455K - Jun 12, 2025ARQT
Arcutis Biotherapeutics, Inc.
AwardDirect7.6K shares- - Jun 12, 2025PCVX
Vaxcyte, Inc.
AwardDirect3K shares- - Jun 11, 2025CTMX
CytomX Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
38K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 17, 2026 |  CTMX CytomX Therapeutics, Inc. | Award Stock Option (Right to Buy) | 59,000 | - | - | Direct |
| Jun 15, 2026 |  PCVX Vaxcyte, Inc. | Award | 2,265 | - | $0 | Direct |
| Jun 5, 2026 |  ARQT Arcutis Biotherapeutics, Inc. | Award | 5,778 | - | $0 | Direct |
| Nov 20, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Exercise | 12,220 | $7.51 | $91,772 | Direct |
| Nov 20, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Sale | 16,532 | $27.55 | $455,442 | Direct |
| Jun 12, 2025 | ARQT Arcutis Biotherapeutics, Inc. | Award | 7,609 | - | - | Direct |
| Jun 12, 2025 | PCVX Vaxcyte, Inc. | Award | 3,041 | - | - | Direct |
| Jun 11, 2025 | CTMX CytomX Therapeutics, Inc. | Award Stock Option (Right to Buy) | 38,000 | - | - | Direct |
1-8 of 8 transactions